FindTrial
Sign In

Oral Beclometasone dipropionate for for gut GVHD

Oral Beclometasone dipropionate for for gut GVHD - BDP for gut GVHD

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000031703
Enrollment
1
Registered
2018-03-15
Start date
2018-03-15
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gut Graft-versus-host disease

Interventions

oral beclometasone treatment for four months

Sponsors

Department of Pediatrics, University of Ryukyus, hospital
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: a pediatric case with steroid dependent gut gVHD

Exclusion criteria

Exclusion criteria: no active cytomegalovirus (CMV) infection and no CMV antigenemia for confirmed endoscopically gut GVHD

Design outcomes

Primary

MeasureTime frame
Efficacy for upper/lower digestive symptom at four months after treatment by NIH GVHD response criteria—

Countries

Japan

Contacts

Public ContactSatoru Hamada

University of Ryukyus, hospital Department of Pediatrics

shamada@med.u-ryukyu.ac.jp0988953331

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026